Modernizing the Purification Toolbox for Multi-Specific Antibodies, CRISPR and Cell and Gene Therapies

Modernizing the Purification Toolbox for Multi-specific antibodies, CRISPR and Cell and Gene Therapies Harvest time has come for modern biotechnology and biotherapeutics, bringing a cornucopia of products – CRISPR Cas nucleases, therapeutic viruses and cells and engineered tissue constructs – that are defining the medicine of the future. Along with superior therapeutic efficacy, these products feature unprecedented complexity of biomolecular features and range of scales that define their identity, efficacy and safety. In this webinar, our expert speaker Dr. Stefano Menegatti from NC State University, will discuss his team’s approach in leveraging affinity technology to introduce new tools for purifying and characterizing biotherapeutics to match the growing demands of clinics and biotech industries worldwide. Attend this webinar to: • Learn about affinity ligands operating in negative and positive capture mode for the continuous purification of biotherapeutics • Discover first of its kind RNA triggers for the purification of CRIPSR-CAS nucleases via affinity chromatography • Explore the complexity of EIS sensors for one-step quantification of total virus particle and empty capsid quantification Stefano Menegatti Associate Professor, Chemical and Biomolecular Engineering NC State University Chief Technology Officer, LigaTrap Technologies Stefano Menegatti is associate professor in the department of Chemical and Biomolecular Engineering at NC State University. His team focuses on biorecognition phenomena and engineering of synthetic ligands for biological separations, biosensors, and regenerative medicine applications. Together with Mike Daniele at NC State University, Stef co-founded the North Carolina Viral Vector Initiative in Research and Learning (NC-VVIRAL, https://vviral.ncsu.edu/), a consortium of academic, industrial, and non-profit institutes members whose collective mission is to support biotech and biopharma industries with novel technologies and products in the gene-editing and gene-and-cell-therapy fields. Stef's collaborations with academia and industry span across 3 continents, and have resulted in the adoption of technologies utilized for producing plasma proteins, recombinant therapies, and viral vectors for gene therapy. In 2015, Stef co-founded LigaTrap, a company marketing affinity resins for biological separations, where he now serves as Chief Technology Officer.